Novartis delivers strong financial results and four major approvals in second quarter of 2011
0
Novartis International AG /
Novartis delivers strong financial results and four major approvals in second
quarter of 2011
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Novartis achieved 19% sales growth in constant currencies and excellent
operating leverage in the second quarter
* Net sales grew 27% (+19% in constant currencies, or cc) to USD 14.9
billion; first half up 21% (+16% cc) to USD 28.9 billion
* Core operating income rose 29% (+30% cc) to USD 4.2 billion; core margin
up 0.4 percentage points (+2.6 percentage points cc)
* Core EPS increased 23% (+25% cc) to USD 1.48
* Free cash flow grew 39% to USD 3.3 billion
* Shareholder returns and a sound capital structure remain a priority;
limit on dividend payments to 35-60% of net income lifted
* Healthcare portfolio and portfolio rejuvenation strengthen foundation for
future growth
* Diversified healthcare portfolio generated sales and profit growth ahead
of market with strong contributions from Alcon, Sandoz and Consumer
Health
* Recently launched products grew 46% over previous-year quarter to USD
3.8 billion
* Best-in-class Gilenya launch with USD 138 million in first half sales
* Commitment to innovation results in four major approvals and two major
filings
* FDA approved Afinitor for advanced pancreatic neuroendocrine tumors and
Arcapta Neohaler for chronic obstructive pulmonary disease
* EU granted approval for Lucentis in retinal vein occlusion and for
hypertension medicine Rasilamlo
* Janus kinase inhibitor INC424 was filed for myelofibrosis in Europe; FDA
accepted application to expand Menveo indication to toddlers and infants
as young as 2 months
Key figures
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Net sales 14 915 11 716 27 19 28 942 23 847 21 16
Operating income 3 322 2 961 12 15 6 730 6 472 4 7
Net income 2 726 2 437 12 17 5 547 5 385 3 7
EPS (USD) 1.13 1.06 7 12 2.33 2.34 0 3
Free cash flow() 3 297 2 368 39 4 919 5 271 -7
Core[1]
Operating income 4 235 3 276 29 30 8 247 7 141 15 17
Net income 3 564 2 771 29 31 6 940 6 080 14 16
EPS (USD) 1.48 1.20 23 25 2.88 2.65 9 11
[1] See page 44 for further information and definition of core results
Basel, July 19, 2011- Commenting on the results, Joseph Jimenez, CEO of
Novartis, said:
"Excellent execution behind a sound strategy resulted in another successful
quarter for Novartis. We achieved strong sales growth of 19% in constant
currencies and margin improvement of 0.4 percentage points in US dollars. We
further demonstrated the success of our R&D strategy with four major approvals
and two filings in the second quarter. Our diversified healthcare portfolio,
focused on high growth segments, is enabling us to generate superior results."
GROUP REVIEW
Second quarter
Net sales rose 27% (+19% cc) to USD 14.9 billion. Currency benefited sales by
8% as the US dollar weakened against most currencies. Recently launched products
grew 46% over the previous-year quarter, contributing USD 3.8 billion to total
net sales for the Group.
Pharmaceuticals net sales grew 10% (+2% cc) to USD 8.3 billion, driven by 8
percentage points of volume growth, partly offset by a negative pricing impact
of 1 percentage points and the negative impact of generic entries and product
divestments of 5 percentage points. Recently launched products contributed USD
2.3 billion or 28% of Pharmaceuticals sales, an increase of 34% in constant
currencies over the second quarter of 2010. Alcon contributed USD 2.6 billion of
net sales in the second quarter. On a pro forma basis, Alcon grew 12% (+6% cc),
with robust growth across geographies and products. Sandoz had an excellent
quarter with net sales up 25% (+16% cc) to USD 2.5 billion, driven by 26
percentage points of volume growth, partly offset by a negative pricing impact
of 13 percentage points. Vaccines & Diagnostics declined 47% (-50% cc) due to
A(H1N1) pandemic flu vaccine sales of approximately USD 200 million in the
second quarter of 2010; excluding this, sales declined due to timing of product
shipments to key customers. The two Consumer Health businesses, OTC and Animal
Health, together grew 5% in constant currencies. OTC´s strong growth ahead of
market was driven by US, Canada and Germany as well as double-digit net sales
growth in key emerging markets. Animal Health achieved strong performance in
Europe and emerging markets, which offset increasing competition in the US
Companion Animal Business compared to last year.
Operating income was up 12% (+15% cc). Currency had a negative impact of 3%, as
the benefit of a weaker dollar against most currencies was offset by an
exceptionally strong Swiss franc. Exceptional items in operating income in the
second quarter of 2011 include a divestment gain of USD 324 million on the sale
of Elidel®, offset by impairment charges in Vaccines & Diagnostics (USD 62
million) and Pharmaceuticals (USD 107 million), provisions for legal cases in
Sandoz (USD 150 million), restructuring and impairment charges relating to the
streamlining of our manufacturing network (USD 44 million) and Alcon integration
costs (USD 80 million).
Core operating income, which excludes exceptional items and amortization of
intangible assets, increased 29% (+30% cc). We generated excellent operating
leverage in the quarter with core operating income margin increasing by 2.6
percentage points in constant currencies. Currency reduced the core operating
margin by 2.2 percentage points, resulting in a net increase of 0.4 percentage
points to 28.4 %. Pharmaceuticals grew core operating income by 6% in constant
currencies on good cost management; Alcon contributed USD 947 million to core
operating income, growing 12% (+8% cc) on a pro forma basis; Sandoz was up by
49% in constant currencies; and Consumer Health was up by 9% in constant
currencies. Vaccines & Diagnostics reported a loss from the absence of A(H1N1)
pandemic flu vaccine revenues and continued investment in the meningococcal
disease and early vaccines portfolio.
Net income increased 12% (+17% cc) on strong operating income growth, benefiting
from an improved tax rate of 16.0% (17.6% in the previous-year period),
partially offset by lower income from associated companies. Core net income grew
29% (+31% cc). EPS advanced 7% (+12% cc) and core EPS was up by 23% (+25% cc) at
a lower rate than net income as a result of the Alcon related share increase.
Free cash flow of USD 3.3 billion was 39% higher than in the previous year,
primarily due to higher operating income, cash inflow for the Elidel® divestment
(USD 420 million) and improved working capital.
First half
Net sales rose 21% (+16% cc) to USD 28.9 billion. Currency had a positive impact
of 5 percentage points as the US dollar weakened against most currencies.
Recently launched products grew 47% over the first half of 2010, contributing
USD 7.1 billion to total net sales for the Group.
Pharmaceuticals net sales grew 8% (+3% cc) to USD 16.0 billion, driven by 8
percentage points of volume growth, partly offset by a negative pricing impact
of 1 percentage points and the negative impact of generic entries and product
divestments of 4 percentage points. Recently launched products contributed 27%
of Pharmaceuticals sales (USD 4.3 billion), compared to 21% in the same period
in 2010. Alcon contributed USD 5.0 billion of net sales in the first half,
growing 11% (+7% cc) on a pro forma basis, underpinned by strong growth in
surgical and ophthalmic pharmaceuticals. Sandoz sales grew 22% (+17% cc)
compared to the first half of 2010, driven by 25 percentage points of volume
growth, led by strong performances in the US, Canada, Western Europe and
emerging markets, which more than compensated for 11 percentage points of price
erosion. Vaccines & Diagnostics declined 65% (-66% cc) due to 2010 A(H1N1)
pandemic flu vaccine sales of USD 1.3 billion; excluding this, sales grew 6% in
constant currencies driven by our meningococcal disease and influenza
franchises. The two Consumer Health businesses delivered good sales growth of
13% (+8% cc) in the first half of 2011, with both OTC and Animal Health
outpacing their respective markets.
Operating income advanced 4% (+7% cc), with currency movements depressing the
result by 3 percentage points. Exceptional items in operating income in the
first half of 2011 include divestment gains in Pharmaceuticals on the sale of
ophthalmic pharmaceuticals required for approval of the Alcon merger (USD 81
million), a gain of USD 183 million resulting from a legal settlement in the
Alcon Division and USD 324 million in divestment income from the sale of
Elidel®. These positive items were offset by charges and provisions for legal
cases (Sandoz USD 178 million), restructuring and impairment charges relating to
the streamlining of our manufacturing network (USD 99 million), the impairment
of financial assets in Vaccines & Diagnostics (USD 81 million), intangible asset
impairment charges in Pharmaceuticals (USD 107 million) and Alcon integration
costs net of a divestment gain of a lens care product (USD 71 million).
Core operating income, which excludes exceptional items and amortization of
intangible assets, increased 15% (+17% cc). We generated good operating leverage
in the first half with core operating income margin increasing by 0.3 percentage
points in constant currencies. Currency reduced the core operating margin by
1.7 percentage points, resulting in a net decrease of 1.4 percentage points to
28.5 %. Pharmaceuticals achieved core operating income growth of 7% (+8% cc) due
to good cost management. Alcon contributed USD 1.8 billion to core operating
income, growing 10% (+8% cc) on a pro forma basis. Vaccines & Diagnostics
reported an operating loss mainly due to the absence of A(H1N1) pandemic flu
vaccine revenues (USD 1.3 billion in 2010). Sandoz was up by 31% (+33% cc) and
Consumer Health was up by 17% (+26% cc).
Net income grew 3% (+7% cc) on strong operating income growth, benefiting from
an improved tax rate of 16.0% (from 17.0%), partially offset by lower income
from associated companies. Core net income increased 14% (+16% cc). EPS was USD
2.33, broadly in line with the previous year as a result of the increased share
count following the Alcon merger. Core EPS was USD 2.88, an increase of 9% (+11%
cc).
Free cash flow of USD 4.9 billion was 7% lower than the previous year, primarily
due to higher seasonal working capital.
Executing on innovation, growth and productivity
The Novartis growth strategy is based on providing a comprehensive set of
healthcare solutions. We are the only healthcare company with leading positions
in pharmaceuticals, eye care, generics, vaccines and diagnostics, over-the-
counter medicines and animal health.
We expect our broad portfolio to allow us to maintain our growth momentum into
the future and adapt ahead of changes to the healthcare marketplace. At the core
of this strategy is our continued commitment to innovation, growth and
productivity: innovation to expand and rejuvenate our portfolio and allow us to
bring new healthcare solutions to patients in need; growth to enter new markets
and meet the changing demands of patients around the world; and productivity to
operate as efficiently as possible, freeing up resources for future investment
in R&D.
Accelerating growth to provide healthcare solutions worldwide
In the second quarter, our diversified healthcare portfolio once again generated
growth ahead of the market, with Alcon, Sandoz and Consumer Health delivering
particularly strong performances. Benefiting from our continued investment in
innovation to expand and rejuvenate our portfolio, recently launched products
achieved strong volume growth in the second quarter, allowing us to absorb the
effects of pricing, generic competition and divestments. Overall we achieved an
underlying volume growth of 7%.
In line with our overall growth strategy, emerging markets are increasingly
contributing to our business expansion. Net sales in our top six emerging
markets rose 27% (+19% cc) to USD 1.5 billion in the second quarter of 2011.
These six markets - Brazil, China, India, Russia, South Korea and Turkey -
represented 10% of total net sales in the quarter. Reflecting our commitment to
accelerating growth in dynamic new markets worldwide, we started construction on
a new state-of-the-art manufacturing facility in St. Petersburg, Russia. This
investment is part of a greater commitment in local infrastructure and
collaborative healthcare initiatives planned in Russia over a five-year period.
Pharmaceuticals volume grew 8% in the second quarter, with significant
contributions from recently launched products more than offsetting generic
competition. In particular, Gilenya, launched in the US in October 2010 and in
parts of the EU following approval in March 2011, is continuing its strong
growth trajectory and outpacing all previous launches in multiple sclerosis with
sales of USD 79 million in the second quarter. Tasigna (USD 170 million, +79%
cc) also provided strong growth as a next-generation targeted therapy for
chronic myeloid leukemia (CML), as studies continue to show its superiority even
to Glivec in treating patients with this life-threatening blood cancer. Tasigna
now represents 17% of our total CML franchise in the US, where it was launched
in the third quarter of 2010. Additionally, Lucentis (USD 541 million, +27% cc)
made an important contribution to Pharmaceuticals growth, as it continues to be
the only approved medicine to significantly improve vision in patients with wet
age-related macular degeneration (AMD). Furthermore, in the first half of 2011,
two new indications were granted for Lucentis in the EU in diabetic macular
edema and retinal vein occlusion.
The new Alcon Division, which now also includes the CIBA Vision contact lens and
lens care business and select Novartis ophthalmic medicines, delivered robust
growth in the second quarter. With the new organizational structure implemented
in the second quarter, Alcon is now a fully integrated division of Novartis. Pro
forma net sales rose 12% (+6% cc) to USD 2.6 billion with balanced contributions
across geographies and products, fueled by the successful execution of new
product launches. Sales in markets outside the US contributed strongly to
overall growth with sales up 18% (+7% cc), driven by the ophthalmic
pharmaceutical and surgical product categories. Sales in the top six emerging
markets increased 29% (+21% cc), led by Russia, India and China. Alcon also
achieved an important milestone in the second quarter for Patanol, the world´s
leading prescription eye drop for allergic conjunctivitis, prevailing in a US
patent infringement lawsuit in the Southern District of Indiana. The US District
Court´s decision will help Alcon defend its intellectual property rights ahead
of Patanol´s patent expiration in 2015.
Sandoz continued its strong performance in the second quarter, achieving double-
digit growth of 25% (+16% cc), driven by strong results in the US, where growth
was up 48% in constant currencies, Western Europe (+19% cc) and Latin America
(+18% cc). Another key driver of growth for Sandoz was our continued strength in
biosimilars, with second-quarter sales up 31% in constant currencies over the
previous year. Recently launched products, such as enoxaparin, gemcitabine and
lansoprazole oral disintegrating tablets, also made significant contributions to
overall growth.
Vaccines & Diagnostics declined 47% (-50% cc) in the second quarter due to 2010
A(H1N1) pandemic flu vaccine sales (approximately USD 200 million). Excluding
this, sales declined due to delays of product shipments from one production
facility, partially offset by second-quarter growth in the meningococcal disease
and influenza franchises.
The Consumer Health businesses also performed well, growing 13% (+5% cc) in the
second quarter versus previous year. The continued focus of OTC on priority
brands delivered strong results, with several of those brands growing at a
double-digit rate over the prior-year period, offsetting a sales decline from
expired distribution contracts and divested brands. Animal Health grew ahead of
the market outside the US in the second quarter, with strong sales of the cat
and dog dewormer Milbemax in Europe and of the anti-infective Denagard in the
US, China and Brazil. Strong growth in the top six emerging markets in both
businesses contributed significantly to overall performance.
Investing in innovation
The foundation of our success is our ability to develop new innovative
treatments. Our industry-leading commitment to R&D enables us to continually
expand our pipeline, leading to sustained growth. More importantly, we expect
our R&D investments to allow us to achieve breakthroughs in crucial areas of
unmet patient need. In the second quarter of 2011, we made important strides in
innovation, with four major approvals, two major filings and significant results
for new products and indications.
Four major approvals
In Europe, Rasilamlo, our single-pill combination therapy for patients with
uncontrolled high blood pressure, was granted approval. We also received EU
approval for a new indication of Lucentis to treat visual impairment due to
macular edema in patients suffering from retinal vein occlusion (RVO), a sudden-
onset disease associated with debilitating vision loss.
In the US, the FDA granted approval for Arcapta Neohaler (indacaterol), a novel
once-daily bronchodilator for chronic obstructive pulmonary disease (COPD). The
FDA also approved Afinitor (everolimus) as the first new treatment in nearly
three decades for patients with advanced neuroendocrine tumors of pancreatic
origin, a highly aggressive cancer for which treatment options have been
limited.
Additionally, indacaterol was approved in Japan under the brand name Onbrez
Inhalation Capsules. Everolimus was approved in Switzerland under the name
Votubia as a treatment for subependymal giant cell astrocytoma (SEGA), a benign
brain tumor associated with tuberous sclerosis, and received a positive opinion
from the EMA´s Committee for Medicinal Products for Human Use (CHMP) for
approval in Europe.
Two major filings
We filed an application in the EU for our in-licensed Janus kinase inhibitor
INC424 to treat patients with myelofibrosis, a life-threatening blood cancer
characterized by bone marrow failure and debilitating symptoms. In addition, the
FDA accepted our application to expand the indication of our meningococcal
vaccine Menveo to include infants and toddlers as young as 2 months, based on
data from more than 6,000 children in this age group worldwide.
Significant pipeline news
At the American Society of Clinical Oncology (ASCO) annual meeting, Oncology
showcased 140 abstracts. Highlights include a Phase III study demonstrating that
extending the post-surgical duration of Glivec treatment from one to three years
can significantly improve survival in patients with gastrointestinal stromal
tumors. In addition, we presented data from two Phase III studies of the Janus
kinase inhibitor INC424 that show promise for patients with myelofibrosis, a
life-threatening blood cancer characterized by bone marrow failure and
debilitating symptoms. We also presented a study of patients with chronic
myeloid leukemia that shows patients on Tasigna are less likely to develop
mutations than those taking Glivec.
Also in the second quarter, two Phase III studies in patients with severe gouty
arthritis showed that ACZ885, currently marketed as Ilaris for the rare disease
cryopyrin-associated periodic syndrome (CAPS), provides superior pain relief and
reduces the risk of new attacks by up to 68% compared to the anti-inflammatory
standard of care. On June 21, 2011, an FDA advisory panel voted in favor of the
overall efficacy but not the overall safety of ACZ885 to treat gouty arthritis
attacks in patients not obtaining adequate relief with non-steroidal anti-
inflammatory drugs or colchicine. The committee members raised the potential for
use in a narrower population of gouty arthritis patients, and Novartis is
currently working with the FDA to identify the right patients who might benefit
from this therapy.
In addition, two Phase III studies added to the growing body of evidence that
indacaterol, approved in the EU under the brand name Onbrez Breezhaler, is an
effective treatment for patients with chronic obstructive pulmonary disease
(COPD). The studies showed that when used in conjunction with tiotropium,
indacaterol produces a significantly greater improvement in lung function than
tiotropium alone. Separately, a Phase III study showed that once-daily NVA237 is
superior to placebo and similar to tiotropium in improving lung function in
patients with moderate-to-severe COPD. This data will be used to support our
first regulatory submission for NVA237, which we plan to file by the end of
2011.
In July, an interim analysis of a pivotal Phase III study showed that Afinitor
in combination with exemestane significantly extended progression-free survival,
or time without tumor growth, when compared to placebo plus exemestane in
postmenopausal women with metastatic breast cancer whose disease has progressed,
despite initial endocrine therapy. We are planning to make worldwide regulatory
submissions in the second half of 2011. Additionally, a Phase III trial of
Afinitor in patients with tuberous sclerosis met the primary endpoint of
reducing subependymal giant cell astrocytomas (SEGAs) tumor size.
In Vaccines and Diagnostics, two pivotal studies of vaccine candidate Bexsero
showed promise for protecting infants against meningococcal serogroup B, a
deadly strain of meningococcal disease most dangerous for infants and young
children.
Enhancing productivity to reinvest for future growth
In order to free up resources and ensure continued investment in R&D, we are
focused on improving efficiency and reducing costs across the entire business.
We delivered good operating leverage in the second quarter with sales growing
19% (cc), core operating income up 30% (cc) and core operating income margin
improving by 2.6 percentage points (cc). On an underlying basis - excluding the
impact of A(H1N1) pandemic flu vaccine from 2010 and the merger with Alcon -
core operating income margin improved by 2.3 percentage points (cc). This
demonstrates the progress the Group continues to make to drive productivity and
improve operating performance. In the first half, underlying core operating
income margin improved by 2.2 percentage points (cc).
Part of maximizing productivity is actively managing and prioritizing our
portfolio. In the second quarter, we sold the global rights to manufacture,
market and commercialize Elidel® to Meda for a total cash payment of USD 420
million. This agreement, as well as the discontinuation of the development
program PTK796, reflects our strategy of prioritizing investments and focusing
our commercialization efforts on new product launches and core brands.
We also made further progress in our efforts to optimize our manufacturing
footprint. We concluded the divestment of a Sandoz site in Jena, Germany, and
announced our exit from a CIBA Vision production site in Cidra, Puerto Rico. We
recorded charges related to exits and inventory write-offs of USD 44 million in
the second quarter of 2011, and USD 162 million cumulatively since the program
began in the fourth quarter of 2010. With these steps we are reducing excess
capacity and enabling the shift of strategic production to technology competence
centers.
Cash flow
The sustainability of our strategy lies with the generation of cash flow that
provides the resources for reinvestment and creates shareholder return. Cash
flow is driven by a continued focus on the cash conversion cycle and operational
cash flow improvements. Free cash flow was USD 3.3 billion for the second
quarter, an increase of 39% over the previous year. For the first half free cash
flow was USD 4.9 billion, 7% lower than the previous year.
Capital structure and net debt
Strong cash flows and a sound capital structure have allowed Novartis to invest
in the future of its business through R&D investments and acquisitions even in
turbulent times while keeping a double-A rating as a reflection of financial
strength. Retaining a good balance between attractive shareholder returns,
investment in the business and a sound capital structure will remain a priority
in the future. To this end, the Board of Directors has decided to remove the
restriction that limits the payment of dividends to 35-60% of net income.
During the quarter, Novartis completed the share repurchase program committed to
at the time of the Alcon merger announcement. This program aggregated USD 5.0
billion, of which USD 1.8 billion (30 million shares) was undertaken in the
second quarter.
As of June 30, 2011, net debt stood at USD 21.9 billion, with USD 6.0 billion
outstanding on the commercial paper programs. This represents a net increase of
USD 7.0 billion since December 31, 2010, mainly as a result of the cash used for
the dividend payment (USD 5.4 billion) as well as Alcon related share
repurchases and contingent value amount (USD 5.3 billion). The long-term credit
rating for the company continues to be double-A (Moody´s Aa2; Standard & Poor´s
AA-; Fitch AA).
2011 Group outlook
(Barring unforeseen events)
During the second quarter, the Group revised its divisional structure following
the successful completion of the Alcon merger on April 8, 2011 and the majority
acquisition in August 2010. All data in this release is based on the new
divisional structure, published on May 18, 2011, including the outlook.
Group constant currency sales growth is expected to be around the double-digit
mark, based on consolidation of Alcon for four months in 2010.
Pharmaceuticals is expected to deliver sales growth in low- to mid-single
digits, with volume growth more than offsetting the impact of generic
competition. Alcon sales are expected to increase at a mid- to high-single digit
rate on a pro forma basis. Sandoz is expected to deliver mid- to high-single
digit sales growth.
With the continuing drive to generate productivity improvements across the
Group, we expect to improve constant currency core operating income margin while
absorbing price cuts, generic competition and the loss of sales from the A(H1N1)
pandemic flu vaccine, and while investing for the future.
During the second quarter, the dollar weakened against most currencies. As a
result, if June average exchange rates prevail for the remainder of the year, we
expect that the impact would be positive (+5%) on sales and negative (-3%) on
operating income for the full year.
HEALTHCARE BUSINESS REVIEW
Pharmaceuticals
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Net sales 8 338 7 609 10 2 16 036 14 836 8 3
Operating income 2 791 2 260 23 25 5 252 4 505 17 19
As % of net sales 33.5 29.7 32.8 30.4
Core operating income 2 699 2 560 5 6 5 241 4 910 7 8
As % of net sales 32.4 33.6 32.7 33.1
Second quarter
Net sales
Net sales grew 10% (+2% cc) to USD 8.3 billion, driven by 8 percentage points
volume growth, partly offset by a negative pricing impact of 1 percentage point
(mainly due to healthcare cost-containment measures) and a combined effect of
generic entries and product divestments of an additional 5 percentage points.
Products launched since 2007 generated USD 2.3 billion of net sales, growing
34% in constant currencies over the same period last year. These recently
launched products - which include Lucentis, Exforge, Exelon Patch, Exjade,
Reclast/Aclasta, Tekturna/Rasilez, Tasigna, Afinitor, Onbrez Breezhaler, Ilaris,
Fanapt and Gilenya - now comprise 28% of division sales, compared to 21% in the
same period last year.
Europe (USD 3.1 billion, +3% cc) particularly benefited from recently launched
products, which accounted for 34% of net sales in the region. Europe maintained
strong volume growth of 10 percentage points, more than offsetting a negative
pricing impact of 5 percentage points and the effect of generic entries of 2
percentage points. Despite strong launches for Tasigna and Gilenya, US sales
(USD 2.5 billion, -2% cc) declined versus the same period last year due to
Femara and Lotrel high-strength dose generic competition, as well as the
Enablex® divestment. Latin America and Canada (USD 0.8 billion, +8% cc) achieved
solid growth rates. Japan´s sales (USD 0.9 billion, -2% cc) declined versus the
same period last year impacted by stock-in-trade movements following wholesaler
safety stocking related to the natural disaster in the first quarter of 2011.
The top six emerging markets (USD 0.9 billion, +5% cc) were led by particularly
strong growth in China and India.
All strategic franchises contributed to the business expansion. Oncology (USD
2.7 billion, +2% cc), the largest franchise, was underpinned by the sustained
growth of Gleevec/Glivec and Tasigna (USD 1.4 billion, +10% cc), as well as
Sandostatin (USD 365 million, +10% cc) and the recently launched Afinitor, which
added USD 102 million (+72% cc). Femara (USD 241 million, -36% cc) was impacted
by generics entry in the US. The Cardiovascular and Metabolism franchise (USD
2.1 billion, +2% cc) maintained solid momentum supported by the continued strong
uptake of Galvus (USD 165 million, +65% cc). The Neuroscience and Ophthalmics
franchise (USD 1.1 billion, +18% cc) saw solid growth from Lucentis (USD 541
million, +27% cc) and the recently launched Gilenya (USD 79 million), which has
shown strong sales following launches in both the US and Europe.
Operating income
Operating income increased 23% (+25% cc) to USD 2.8 billion, including
divestment income from Elidel® (USD 324 million), which more than offset
intangible asset impairment charges (USD 107 million), mainly resulting from the
discontinuation of the PTK796 development program.
Core operating income grew 5% (+6% cc) to USD 2.7 billion. In constant currency,
core operating income margin improved by 1.3 percentage points due to continuing
productivity efforts. Currency movements negatively impacted core margin by 2.5
percentage points resulting in core operating income margin of 32.4% of net
sales. Gross margin improved by 0.2 percentage points before negative currency
effects of 1.2 percentage points. R&D expenses improved by 1.0 percentage points
of net sales in constant currency. Marketing & Sales and General &
Administration expenses improved margin by 0.9 percentage points (cc),
benefiting from ongoing productivity efforts that more than offset significant
investments in new product launches. Other Income & Expense, net reduced margin
by 0.8 percentage points (cc) mainly due to a fee associated with healthcare
reform in the US.
First Half
Net sales
Net sales expanded 8% (+3% cc) to USD 16.0 billion driven by 8 percentage points
of volume growth, partly offset by a negative pricing impact of 1 percentage
point and the impact of generic entries and product divestments of an additional
4 percentage points. Recently launched products provided USD 4.3 billion of net
sales, representing 27% of net sales compared to 21% in the 2010 period.
Europe remained the largest region (USD 5.9 billion, +3% cc) for
Pharmaceuticals, particularly benefiting from recently launched products, which
generated 33% of net sales. The US (USD 4.9 billion, flat in cc) contributed
31% of total sales for the division. Japan´s performance (USD 1.8 billion, 4%
cc) improved versus prior year due to new launches. Latin America and Canada
(USD 1.5 billion, +10% cc) maintained solid growth rates. The top six emerging
markets (USD 1.6 billion, +5% cc) were led by double-digit growth from China and
India.
Operating income
Operating income grew 17% (+19% cc) to USD 5.3 billion, including divestment
income from Elidel® (USD 324 million) and ophthalmic products related to the
Alcon acquisition (USD 81 million), more than offsetting impairment charges of
USD 107 million.
Core operating income grew 7% (+8% cc) to USD 5.2 billion. In constant currency,
core operating income margin improved by 1.6 percentage points due to continuing
productivity efforts. Currency movements negatively impacted core margin by 2.0
percentage points resulting in a core operating income margin of 32.7% of net
sales. The underlying gross margin improved by 0.5 percentage points (cc).
Functional costs decreased by 1.9 percentage points from continuing productivity
efforts despite significant investments in new product launches. Other Income &
Expense, net increased by 0.8 percentage points (cc), mainly due to a fee
associated with healthcare reform in the US.
Pharmaceuticals product review
All comments below focus on second quarter movements.
Cardiovascular and Metabolism
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Hypertension medicines
Diovan 1 513 1 552 -3 -8 2 918 2 994 -3 -6
Exforge 308 227 36 26 569 431 32 26
Tekturna/Rasilez 159 103 54 45 290 192 51 46
Subtotal 1 980 1 882 5 -1 3 777 3 617 4 0
Galvus 165 90 83 65 297 166 79 68
Total strategic products 2 145 1 972 9 2 4 074 3 783 8 3
Established medicines 260 348 -25 -32 522 716 -27 -31
Total 2 405 2 320 4 -3 4 596 4 499 2 -2
Our Hypertension franchise, consisting of Diovan, Exforge and Tekturna/Rasilez,
maintained its strong position in the second quarter as our portfolio continues
to shift from Diovan to Exforge and Tekturna/Rasilez.
Diovan Group (USD 1.5 billion, -8% cc) worldwide sales started to decline from
the anticipated entry of generic valsartan in select markets, such as Spain,
Canada and Brazil. In key markets like China, LATAM as well as in Japan, we are
expecting sustained Diovan performance despite loss of exclusivity in the EU and
US. The Diovan Group maintained its position as the top-selling branded anti-
hypertensive medication worldwide, with global market share of 13.7% of the
hypertension market in YTD May 2011 (+0.3 ppts over previous year) versus 13.4%
in YTD May 2010.
Exforge Group (USD 308 million, +26% cc) showed strong worldwide growth fuelled
by continued prescription demand in the EU, US and other key regions, as well as
ongoing Exforge HCT launches in Europe, Asia and Latin America. Exforge, a
single-pill combination of Diovan (valsartan) and the calcium channel blocker
amlodipine, has delivered sustained growth globally since its launch in 2007.
Exforge launches are ongoing in China and Japan, two key markets with
particularly high usage of calcium channel blockers. Exforge HCT, the first
modern triple hypertension medication that includes a diuretic in a single pill,
is now available for patients in over 35 countries with additional launches
expected over 2011 and 2012.
Tekturna/Rasilez (USD 159 million, +45% cc) maintained strong growth driven by
solid sales worldwide, including in the EU, US, Latin America and Japan. The
Tekturna/Rasilez market share of the total anti-hypertensive market has
increased 0.35 ppts to reach 1.1% (YTD May 2011).
Galvus Group (USD 165 million, +65% cc), which comprises oral treatments
containing vildagliptin for type 2 diabetes, continued to deliver strong growth,
driven largely by strong growth in Japan, as the two-week restriction was
lifted. The single-pill combination Eucreas/Galvus (vildagliptin and metformin)
contributed 68% of total sales, growing 63% in the second quarter. The Galvus
Group is outgrowing Januvia® in Europe and Asia.
Oncology
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Bcr-Abl Franchise
Gleevec/Glivec 1 203 1 075 12 4 2 279 2 107 8 3
Tasigna 170 89 91 79 323 164 97 88
Subtotal 1 373 1 164 18 10 2 602 2 271 15 9
Zometa 376 378 -1 -7 749 753 -1 -5
Femara 241 338 -29 -36 595 682 -13 -17
Sandostatin 365 312 17 10 702 622 13 9
Exjade 232 192 21 12 411 371 11 5
Afinitor 102 55 85 72 192 96 100 90
Other 39 41 -5 -24 75 90 -17 -25
Total 2 728 2 480 10 2 5 326 4 885 9 4
Our Bcr-Abl franchise, consisting of Gleevec/Glivec and Tasigna, continued to
grow strongly, reaching USD 1.4 billion (+10% cc) in the second quarter
Gleevec/Glivec (USD 1.2 billion, +4% cc) continued to grow as a targeted therapy
for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), and as
a metastatic, unresectable and adjuvant (post-surgery) treatment of
gastrointestinal stromal tumors (GIST).
Tasigna (USD 170 million, +79% cc) has been growing rapidly as a next-generation
targeted therapy for adult patients newly diagnosed with Ph+ CML in chronic
phase. We have achieved regulatory approvals for Tasigna in the first-line
indication in 50 markets globally, including the US, EU, Japan and Switzerland,
with additional submissions pending worldwide. Tasigna continues to grow market
share in the imatinib resistant/intolerant Ph+ CML chronic phase and accelerated
phase segments with approvals in over 90 countries.
Zometa (USD 376 million, -7% cc) is a leading treatment to reduce or delay
skeletal-related events in patients with bone metastases from solid tumors and
multiple myeloma. Sales declined in the second quarter due to new competition.
Femara (USD 241 million, -36% cc), a treatment for early stage and advanced
breast cancer in postmenopausal women, experienced a decline in sales due to
multiple generic entries in the US and other key markets.
Sandostatin (USD 365 million, +10% cc) continues to benefit from the increasing
use of Sandostatin LAR in key markets for treatment of symptoms associated with
neuroendocrine tumors. It is also approved as treatment for patients with
acromegaly.
Exjade (USD 232 million, +12% cc) continues to grow at a double-digit rate. It
is currently approved in more than 100 countries as the only once-daily oral
therapy for transfusional iron overload.
Afinitor (USD 102 million, +72% cc), an oral inhibitor of the mTOR pathway,
continued to achieve strong growth in key markets as the only approved treatment
for patients with advanced renal cell carcinoma following VEGF-targeted therapy.
The active ingredient, everolimus, is approved in the US for the treatment of
pancreatic neuroendocrine tumors and SEGA associated with tuberous sclerosis as
Afinitor, and is also approved in Switzerland for the treatment of SEGA
associated with tuberous sclerosis under the trade name Votubia. Everolimus is
exclusively licensed to Abbott and sublicensed to Boston Scientific for use in
drug-eluting stents.
Neuroscience and Ophthalmics
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Lucentis 541 377 44 27 985 741 33 23
Exelon/Exelon Patch 264 252 5 -3 515 503 2 -2
Comtan/Stalevo 160 150 7 -1 306 291 5 0
Gilenya 79 0 nm nm 138 0 nm nm
Extavia 44 38 16 4 78 58 34 26
Fanapt 7 0 nm nm 16 21 -24 -23
Other 25 46 -46 -60 62 86 -28 -39
Total strategic products 1 120 863 30 18 2 100 1 700 24 16
Established medicines 142 149 -5 -13 278 282 -1 -8
Total 1 262 1 012 25 13 2 378 1 982 20 13
nm - not meaningful
Lucentis (USD 541 million, +27% cc) continued to show strong growth as the only
approved medicine to significantly improve vision in patients with wet age-
related macular degeneration (AMD), for which it is established as the standard
of care, and for the treatment of visual impairment due to diabetic macular
edema (DME). In the second quarter, Lucentis was approved in the EU and
Switzerland for the treatment of visual impairment due to macular edema
secondary to retinal vein occlusion (RVO) and in Switzerland for the treatment
of visual impairment due to DME. Lucentis is approved in more than 90 countries
for the treatment of wet AMD, and in more than 30 countries for the treatment of
visual impairment due to DME or macular edema secondary to RVO. Genentech holds
the rights to Lucentis in the US.
Exelon/Exelon Patch (USD 264 million, -3% cc) combined sales were impacted by
the entry of oral generic competition in the US, despite continued conversion
from oral to transdermal therapy. Exelon Patch, the transdermal form of the
medicine, grew 13% and generated more than 75% of total Exelon sales in the
second quarter, compared to less than 65% in 2010 period. Novartis received
approval for Exelon Patch in Japan in the second quarter for mild-to-moderate
Alzheimer´s disease, and filed an application in the EU for Exelon Patch for the
treatment of Parkinson´s disease dementia (PDD). Exelon Patch is approved for
the treatment of mild-to-moderate Alzheimer´s disease dementia in more than 80
countries, including more than 20 countries where it is also approved for PDD.
Gilenya (USD 79 million) showed continued rapid growth as an oral disease-
modifying treatment for relapsing remitting and/or relapsing forms of multiple
sclerosis in adult patients. With US sales driving overall growth, Gilenya is
now approved in more than 40 countries with regulatory reviews pending around
the world, including in Japan, Taiwan and Brazil. In the US and EU more than
13,000 patients are on the drug, with 85% on commercial product.
Extavia (USD 44 million, +4% cc), the Novartis-branded version of
Betaferon®/Betaseron® (interferon beta-1b) for relapsing forms of multiple
sclerosis, continued to grow in key markets. Extavia has been approved in over
30 countries since its approval in 2009. Betaferon®/Betaseron® are registered
trademarks of Bayer.
Respiratory
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Xolair 125 90 39 30 232 170 36 34
TOBI 70 72 -3 -7 141 137 3 0
Onbrez Breezhaler 26 6 nm nm 46 8 nm nm
Total strategic products 221 168 32 24 419 315 33 30
Established medicines 38 40 -5 -13 88 89 -1 -6
Total 259 208 25 16 507 404 25 22
nm - not meaningful
Onbrez Breezhaler (USD 26 million) demonstrated strong performance in Europe and
Latin America. The drug was first approved in the EU in November 2009 as a once-
daily long-acting beta-2 agonist for the maintenance bronchodilator treatment of
airflow obstruction in patients with chronic obstructive pulmonary disease
(COPD). Onbrez Breezhaler is now approved in more than 60 countries, including
Turkey as of the second quarter of 2011. On July 1, 2011, we received FDA
approval for a 75 mcg once-daily dose of the medicine under its US trade name,
Arcapta Neohaler, and on the same day, Japanese regulatory authorities approved
Onbrez Inhalation Capsules in a 150 mcg once-daily dose.
Xolair (USD 125 million, +30% cc), a biotechnology drug for severe persistent
allergic asthma in Europe and for moderate-to-severe persistent allergic asthma
in the US, grew strongly in Europe, major Latin American markets and Japan.
Xolair is approved in more than 85 countries and a Phase III trial to support
registration in China is ongoing. Launches are continuing across Europe for
Xolair Liquid, a new formulation in pre-filled syringes that enables easier
administration over the original lyophilized formulation. Novartis co-promotes
Xolair with Genentech/Roche in the US and shares a portion of the operating
income.
Integrated Hospital Care
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Neoral/Sandimmun 227 217 5 -5 441 429 3 -4
Myfortic 135 108 25 19 255 208 23 19
Zortress/Certican 50 36 39 27 92 70 31 24
Ilaris 12 6 100 95 23 10 130 127
Other 93 73 27 18 179 140 28 22
Total strategic products 517 440 18 8 990 857 16 9
Established medicines 381 359 6 1 727 689 6 2
Total 898 799 12 5 1 717 1 546 11 6
nm - not meaningful
Zortress/Certican (USD 50 million, +27% cc) is an immunosuppressive medicine to
prevent organ rejection in adult heart and kidney transplant recipients that is
now available in more than 85 countries. It continues to generate solid growth,
particularly in the US market, where it has been available since April 2010 for
adult kidney transplantation under the trade name Zortress. It is exclusively
licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting
stents.
Ilaris (USD 12 million, +95% cc) is available in over 45 countries for the
treatment of adults and children four years of age and older who suffer from
cryopyrin-associated periodic syndrome (CAPS), a group of rare auto-inflammatory
disorders. Ilaris was recently filed for the treatment of CAPS in Japan.
Alcon
% %
Restated Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Net sales 2 625 516 nm nm 5 041 1 023 nm nm
Operating income 371 108 nm nm 895 255 nm nm
As % of net sales 14.1 20.9 17.8 24.9
Core operating income 947 115 nm nm 1 787 270 nm nm
As % of net sales 36.1 22.3 35.4 26.4
nm - not meaningful
% %
Pro forma Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Net sales 2 625 2 346 12 6 5 032 4 520 11 7
Operating income 371 367 1 -8 884 673 31 26
As % of net sales 14.1 15.6 17.6 14.9
Core operating income 947 849 12 8 1 785 1 618 10 8
As % of net sales 36.1 36.2 35.5 35.8
The restated financial figures from the second quarter and first half of 2010
include only CIBA Vision and select Novartis ophthalmic products, and not Alcon.
The pro forma financial figures from the 2010 periods include Alcon, CIBA Vision
and select Novartis ophthalmic products. All of the following comments are based
on pro forma figures.
Second quarter
Net sales
Pro forma net sales rose 12% (+6% cc) to USD 2.6 billion. Alcon´s robust sales
growth was broad-based, with balanced contributions across its geographies and
products, fueled by the successful execution of new product launches.
Sales in non-US markets rose 18% (+7% cc) to USD 1.6 billion with key
contributions from the ophthalmic pharmaceutical and surgical product
categories. Sales in the top six emerging markets increased 29% (+21% cc), led
by Russia, India and China. US sales increased 4% to USD 1.0 billion, driven
mainly by ophthalmic pharmaceutical products, which grew 5%, despite a weak
allergy season compared to the 2010 period. US sales growth was dampened by
lower than expected cataract surgery procedure volume and weakness in contact
lens care.
Operating income
Pro forma operating income rose 1% (-8% cc) to USD 371 million, or 14.1% of net
sales. Second quarter operating income was negatively impacted by the inclusion
of intangible asset amortization charges (USD 474 million), integration costs
(USD 80 million) and other costs mainly related to the optimization of our
manufacturing footprint (USD 22 million).
Pro forma core operating income increased by 12% (+8% cc) to USD 947 million, or
36.1% of net sales. The increase reflects the success of Alcon´s business model
specializing in eye care with a diversified portfolio of high-margin products
across the major eye care categories. Core gross margin declined from 75.2% to
74.3% of net sales due mainly to unfavorable currency movements. R&D expenses
improved by 0.6 percentage points of net sales primarily due to the timing of
licensing activity. General & Administration expenses as a percentage of net
sales remained flat. Alcon achieved operating leverage despite significant
Marketing & Sales investments in emerging markets related to sales force
development and promotion activity.
First half
Net sales
Pro forma net sales rose 11% (+7% cc) to USD 5.0 billion. Alcon´s strong
performance was driven by the top six emerging markets, which together grew 28%
(+21% cc), as well as double-digit growth in ophthalmic pharmaceutical products
globally of 14% (+11% cc).
Operating income
Pro forma operating income rose 31% (+26% cc) to USD 884 million, or 17.6% of
net sales. Operating income in the first half was impacted by the inclusion of
exceptional income from a litigation settlement (USD 183 million), intangible
asset amortization charges (USD 967 million), integration costs (USD 80 million)
and other costs mainly related to the optimization of our manufacturing
footprint (USD 37 million).
Pro forma core operating income increased by 10% (+8% cc) to USD 1.8 billion, or
35.5% of net sales.
Alcon product review (pro forma)
All comments below focus on second quarter movements.
Surgical
% %
Pro forma Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Cataract products 746 683 9 3 1 427 1 325 8 3
Cataract IOLs 336 311 8 1 645 603 7 3
Vitreoretinal products 131 109 20 13 252 208 21 17
Refractive/Other 50 31 61 51 93 62 50 44
Total 927 823 13 6 1 772 1 595 11 7
Global surgical sales in the second quarter were USD 927 million, marking an
increase of 13% (+6% cc) over the prior-year period. Strong growth in emerging
markets contributed to faster sales growth outside the US, while US growth was
negatively affected by lower than expected procedural volume and the expiration
of the new technology government reimbursement program for intraocular lenses.
Global sales of advanced technology intraocular lenses rose 17% (+13% cc),
mostly due to increased adoption by cataract surgeons of the AcrySof IQ Toric
and AcrySof IQ ReSTOR+3.0 products. Sales of AcrySof IQ ReSTOR Toric intraocular
lenses, which are currently only available outside the US, contributed to faster
growth in advanced technology lenses in non-US markets. This positive trend
toward advanced technology intraocular lens adoption is important to offset
pricing pressure in the monofocal segment arising primarily from government
reimbursement changes. The Constellation vitreoretinal surgical system
contributed to sales growth with an increase of 54% (+44% cc) in this category.
In the Refractive segment, solid growth was driven by sales of FS200 and the
EX500 equipment, as well as increased market share in the US.
Ophthalmic Pharmaceuticals
% %
Pro forma Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Glaucoma 334 287 16 9 646 559 16 11
Allergy/Otic/Nasal 266 266 0 -2 519 468 11 8
Infection/inflammation 261 213 23 18 488 412 18 16
Dry Eye/Other 207 184 12 7 400 358 12 9
Total 1 068 950 12 8 2 053 1 797 14 11
Global sales of ophthalmic pharmaceutical products increased 12% (+8% cc) to USD
1.1 billion, dampened by a weak allergy season compared to the 2010 period.
Glaucoma product sales increased 16% (+9% cc) on the strong performance of
combination products DuoTrav and Azarga with combined growth of 56% (+40% cc),
as well as continued solid performance of Travatan and Travatan Z ophthalmic
solutions. Infection/inflammation product sales rose 23% (+18% cc) led by market
share gains for Nevanac ophthalmic suspension and solid performance of Durezol
ophthalmic suspension. Strong results in this category also reflect the
successful launches of several important products in the second quarter,
including the anti-infective Moxeza ophthalmic solution in the US and
formulations of Travatan and DuoTrav ophthalmic solutions without benzalkonium
chloride in the EU. Strong sales of Systane and the new Systane Balance were the
key contributors to growth in dry eye products.
Vision Care
% %
Pro forma Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Contact lenses 440 390 13 4 852 772 10 5
Solutions/Other 190 183 4 -2 355 356 0 -5
Total 630 573 10 2 1 207 1 128 7 2
Global sales of vision care products rose 10% (+2% cc) to USD 630 million. Sales
growth in contact lenses was fueled by the continued strong performance of
AirOptix, which achieved double-digit growth in the second quarter and continues
to lead the market in the multifocal segment. Sales of contact lenses were
impacted by the discontinuation of our specialty contact lens business. Contact
lens care sales grew 4% (-2% cc) on increased usage of hydrogen peroxide
products more than offset by weakness in multi-purpose solutions.
Sandoz
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Net sales 2 466 1 973 25 16 4 839 3 974 22 17
Operating income 283 289 -2 4 695 599 16 20
As % of net sales 11.5 14.6 14.4 15.1
Core operating income 533 364 46 49 1 067 814 31 33
As % of net sales 21.6 18.4 22.1 20.5
Second quarter
Net sales
Sandoz net sales grew strongly to USD 2.5 billion (+16% cc) versus prior year
with 26 percentage points of volume expansion, more than offsetting price
erosion of 13 percentage points. The transfer of Falcon from Alcon contributed
3 additional percentage points of sales growth. Performance was driven by strong
sales of recently launched products, such as enoxaparin (generic Lovenox®) and
gemcitabine (generic Gemzar®), strong performance in the US, Canada, France,
Spain, Italy and Japan, and continued strong growth in biosimilars and
injectables.
US retail generics and biosimilars (USD 849 million, +48% cc) continued its
strong sales trajectory, due in part to the recent, successful first-to-market
launches of enoxaparin (USD 284 million), gemcitabine and lansoprazole oral
disintegrating tablets (ODT). Sandoz enoxaparin sole generic status and
lansoprazole ODT co-exclusivity in the US may not extend through the second
half. Falcon contributed USD 64 million.
German sales of retail generics and biosimilars (USD 339 million, -15% cc)
declined compared to the strong prior-year quarter, absorbing the price impact
of statutory health insurance tenders and new lower reference prices implemented
in 2010, but improving versus performance in the first quarter of 2011. Western
Europe retail generics and biosimilars (+19% cc) grew positively, bolstered by
strong performances in Spain, France, Italy and the United Kingdom. Emerging
markets growth was strong in Latin America (+18% cc). Sandoz sustained its
leading global position in biosimilars (+31% cc) with good momentum based on
recent launches of the oncology indications of Binocrit (epoetin alfa) and
Zarzio (filgrastim), as well as continued growth in Omnitrope (human growth
hormone).
Operating income
Operating income grew 4% in constant currencies to USD 283 million. The
operating income margin decreased 3.1 percentage points to 11.5% of net sales as
a result of a USD 150 million provision for legal cases in the US. The addition
of the Falcon business contributed 0.7 percentage points to operating income
margin.
Core operating income rose 49% in constant currencies to USD 533 million,
resulting in an increase in core operating income margin of 5.1 percentage
points (cc). Currency movements negatively impacted core operating income margin
by 1.9 percentage points resulting in a net 3.2 percentage point increase to
21.6%. Gross margin increased 1.7 percentage points (cc), driven by strong sales
growth, COGS productivity programs and the inclusion of the Falcon business,
which more than offset price erosion. Marketing & Sales (+1.1 percentage points
cc) improved due to higher productivity, while fully funding investments in
growing businesses. R&D costs improved by +0.7 percentage points cc due to
economies of scale and timing differences in our expenditure on development
projects. General & Administration costs improved by 0.6 percentage points cc
through ongoing cost-containment measures. Other Income & Expense, net improved
mainly due to lower costs of litigation and provisions for legal cases, despite
lower asset disposal gains compared to the prior-year quarter. The addition of
the Falcon business contributed 1.5 percentage points to core operating income
First half
Net sales
Sandoz net sales grew 22% in the first half of 2011 (USD 4.8 billion, +17% cc)
versus prior year, driven by strong growth in US retail generics and biosimilars
(+57% cc), Western Europe (+19% cc) and emerging markets, including Latin
America (+12% cc) and Central and Eastern Europe (+11% cc), as well as continued
strong results from biosimilars (+32% cc). Sales volumes expanded 25 percentage
points due to new product launches, and Falcon contributed 3 additional
percentage points, more than compensating for price erosion of 11 percentage
points.
Operating income
Operating income in the first half of 2011 grew 20% in constant currencies over
the prior year to USD 695 million. The operating margin decreased by 0.7
percentage points to 14.4% of net sales as a result of price erosion and charges
and provisions for legal cases in the US (USD 178 million), partly offset by
productivity improvements and the addition of the Falcon business.
Core operating income rose 33% in constant currencies to USD 1.1 billion, as the
core operating income margin improved by 2.8 percentage points (cc) with
additional sales volume, new product launches and productivity improvements in
all areas more than offsetting declining prices. Currency movements negatively
impacted core operating income margin by 1.2 percentage points to 22.1%.
Vaccines & Diagnostics
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Net sales 299 564 -47 -50 670 1 925 -65 -66
Operating loss/income -214 -42 nm nm -315 797 nm nm
As % of net sales -71.6 -7.4 -47.0 41.4
Core operating loss/income -89 138 nm nm -113 1 061 nm nm
As % of net sales -29.8 24.5 -16.9 55.1
nm - not meaningful
Second quarter
Net sales
Net sales were USD 299 million for the second quarter of 2011 (-50% cc) compared
with USD 564 million in the 2010 period. The prior-year period included
approximately USD 200 million of A(H1N1) pandemic flu vaccine sales that were
not repeated in 2011.
The second quarter is traditionally the low quarter of the year for the
division. Excluding the impact of the A(H1N1) pandemic flu vaccine in both
years, sales are down from the same period in 2010 mainly due to the timing of
product shipments to key customers.
Operating loss/income
Reported operating loss was USD 214 million for the quarter compared to a loss
of USD 42 million for the same period in 2010. The shortfall was largely due to
the operating income associated with A(H1N1) pandemic flu vaccine sales from the
prior year not repeated in the second quarter of 2011. We continued to invest in
our pipeline and the expansion of our meningococcal disease franchise. The
second quarter of 2011 included an impairment of USD 62 million related to a
financial asset, compared to USD 71 million in the prior-year period. 2010
included a legal settlement of USD 45 million.
Core operating loss for the period was USD 89 million compared to an operating
income of USD 138 million for the same period in 2010.
First half
Net sales
Net sales were USD 670 million for the first half of 2011 (-66% cc) compared to
USD 1.9 billion for the year-ago period. The primary driver of net sales
variance against the prior-year period was USD 1.3 billion of A(H1N1) pandemic
flu vaccine sales in the first half of 2010 that were not repeated in the same
period in 2011.
Excluding the impact of the A(H1N1) pandemic flu vaccine in both years, growth
in the first half of 2011 (+6% cc) was driven by our meningococcal disease and
influenza franchises.
Operating loss/income
Reported operating loss was USD 315 million for the first half of 2011 compared
to income of USD 797 million for the same period in 2010. This was largely due
to the operating income associated with A(H1N1) pandemic flu vaccine sales from
the prior year. When comparing to the prior-year period, 2011 included an
impairment of USD 81 million related to a financial asset versus USD 75 million
in 2010. The 2010 period also included a legal settlement of USD 45 million.
Core operating loss for the period was USD 113 million compared to an operating
income of USD 1.1 billion for the same period in 2010.
Consumer Health
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Net sales 1 187 1 054 13 5 2 356 2 089 13 8
Operating income 225 221 2 11 490 378 30 40
As % of net sales 19.0 21.0 20.8 18.1
Core operating income 239 238 0 9 479 411 17 26
As % of net sales 20.1 22.6 20.3 19.7
Second quarter
Net sales
The two Consumer Health businesses - OTC and Animal Health - together delivered
13% growth in the second quarter of 2011 (+5% cc).
OTC continued to grow ahead of its market in the second quarter driven by
double-digit growth in its priority brands and markets. This was partially
offset by sales losses due to the expiry of distribution contracts and the
divestment of several non-core brands. Prevacid24HR maintained solid market
share in the US and benefited from normalized stock movements after the prior-
year launch phase. Germany, the second largest market for Novartis OTC, grew at
a double-digit rate supported by investments in Voltaren, the number one over-
the-counter self-medication product sold in that country. In Canada, another
priority market, Novartis OTC achieved double-digit sales growth underpinned by
the cough and cold franchise and Voltaren. Sales in the key emerging markets
grew 20% in constant currencies driven mainly by Russia and Brazil, where focus
on key brands and investment into sales forces supported growth.
Animal Health grew ahead of the market outside the US in the second quarter,
delivering sales in line with the period a year ago. Sales in the US Companion
Animal Business were negatively affected by a new competitor to Interceptor and
Sentinel in the heartworm and flea categories. Strong double-digit performance
of pig therapeutic Denagard was a positive factor in the Farm Animal Business in
the US, as well as in China and Brazil. In Europe, Milbemax remained the number
one de-wormer for cats and dogs, with the new chewy formulation accelerating
growth. Key emerging markets delivered strong double-digit growth across all of
the countries.
Operating income
Operating income grew 2% (+11% cc) to USD 225 million. The operating income
margin declined by 2 percentage points to 19.0% of net sales with 3.2 percentage
points attributable to currency. Both Consumer Health businesses carry a
relatively high share of their cost base in Switzerland.
Core operating income was flat (+9% cc) with USD 239 million, the core operating
income margin increasing by 0.9 percentage points (cc). Currency movements
negatively impacted core operating income margin by 3.4 percentage points
resulting in a net margin decline of 2.5 percentage points to 20.1%. Gross
margin improved by 1.1 percentage points (cc) as a result of product mix and
productivity gains. Marketing & Sales expenses increased in the second quarter
as a result of investments in advertising and promotion, including strengthened
support for the US parasiticides business and sales force expansion in OTC,
compared to relatively low spend in the prior-year quarter. R&D as well as
General & Administration expenses increased while Other Income & Expense, net,
benefited from one-time income from divestment of non-core brands in OTC.
First half
Net sales
OTC and Animal Health together delivered good sales growth of 13% (+8% cc) in
the first half, with both businesses outpacing their respective markets.
OTC delivered double-digit sales growth driven by the US, Germany, Canada and
key emerging markets. Focused investments into key brands resulted in strong
growth of Voltaren and Fenistil. The key cough and cold brands Theraflu,
Triaminic and Otrivin grew strongly supported by focused investments, well-
executed launches and a relatively strong flu and cough and cold season in
several markets compared with a weak prior-year season. Prevacid24HR benefited
from normalized quarterly stock movements compared with the first half of 2010
and helped to offset sales declines from expired distribution contacts as well
as divested brands.
Animal Health delivered solid mid-single digit sales growth in the first half
year driven by Australia, Germany, Japan and emerging markets. Milbemax grew at
a double-digit rate as the number one cat and dog de-wormer in Europe. In the
swine business, Denagard continued to deliver strong double-digit growth led by
the US, and in the sheep business, Australia maintained its leadership position
with CliK and Vetrazin.
Operating income
Operating income increased 30% (+40% cc) to USD 490 million, with the operating
income margin in the first half of 2011 increasing by 2.7 percentage points to
20.8% of net sales. Operating income in the first half benefited from
exceptional income from divestments of non-core brands in OTC.
Core operating income increased 17% (+26% cc) to USD 479 million, delivering
strong operating leverage in the Consumer Health businesses, with the core
operating income margin up 0.6 percentage points to 20.3% of net sales.
Excluding the negative effect of currency movements, core operating income grew
26% in the first half, supported by continued productivity programs that helped
to offset the negative impact of product mix.
The core operating income margin increased by 3.4 percentage points (cc).
Currency movements negatively impacted core operating income margin by 2.8
percentage points resulting in a net increase of 0.6 percentage points to
20.3%. Gross margin improved by 0.6 percentage points (cc) as a result of
product mix and productivity gains. Marketing & Sales expenses improved by 1.1
percentage points (cc) as a result of sales performance and high investments in
the prior-year quarter due to the US launch of Prevacid24HR. R&D and General &
Administration improved by 0.3 percentage points (cc), while Other Income &
Expense, net, benefited by 1.4 percentage points (cc) from one-time income from
the divestment of several non-core brands in OTC.
FINANCIAL REVIEW
Second quarter and first half
% %
Q2 2011 Q2 2010 change H1 2011 H1 2010 change
USD m USD m USD cc USD m USD m USD cc
Net sales 14 915 11 716 27 19 28 942 23 847 21 16
Divisional operating income 3 456 2 836 22 24 7 017 6 534 7 10
Corporate income & expense,
net -134 125 nm nm -287 -62 363 282
Group operating income 3 322 2 961 12 15 6 730 6 472 4 7
as % of net sales 22.3 25.3 23.3 27.1
Income from associated
companies 130 158 -18 -33 247 261 -5 -20
Financial income -16 14 nm nm 6 63 nm nm
Interest expense -190 -175 9 6 -379 -308 23 22
Taxes -520 -521 0 4 -1 057 -1 103 -4 0
Net income 2 726 2 437 12 17 5 547 5 385 3 7
EPS (USD) 1.13 1.06 7 12 2.33 2.34 0 3
Core operating income 4 235 3 276 29 30 8 247 7 141 15 17
as % of net sales 28.4 28.0 28.5 29.9
Core net income 3 564 2 771 29 31 6 940 6 080 14 16
Core EPS (USD) 1.48 1.20 23 25 2.88 2.65 9 11
nm - not meaningful
Second quarter
Net sales
Net sales rose 27% (+19% cc) to USD 14.9 billion. Currency benefited sales by
8% as the dollar weakened against most currencies. Recently launched products
grew 46% over the previous-year quarter, contributing USD 3.8 billion to total
net sales for the Group.
Corporate income & expense, net
Corporate income & expense, net, which includes the costs of Group headquarters,
totaled USD 134 million. Costs in the prior-year period totaled USD 140 million,
after excluding a USD 265 million exceptional pension plan curtailment gain.
Group operating income
Operating income was up 12% (+15% cc). Currency had a negative impact of 3%, as
the benefit of a weaker dollar against most currencies was offset by an
exceptionally strong Swiss franc. Exceptional items in operating income in the
second quarter of 2011 include a divestment gain of USD 324 million on the sale
of Elidel®, offset by impairment charges in Vaccines & Diagnostics (USD 62
million) and Pharmaceuticals (USD 107 million), provisions for legal cases in
Sandoz (USD 150 million) and restructuring and impairment charges relating to
the streamlining of our manufacturing network (USD 44 million).
Income from associated companies
Income from associated companies decreased by 18% to USD 130 million, primarily
due to the fact that Alcon, Inc. contributed USD 35 million in the prior-year
period. As it is now fully consolidated, it is no longer included as an
associated company.
The following is a summary of the individual components included in the income
from associated companies:
Q2 2011 Q2 2010 H1 2011 H1 2010
USD m USD m USD m USD m
Share of estimated Roche reported net income 163 149 360 307
Restructuring impact -41 -43
Amortization of intangible assets -41 -32 -79 -66
Net income effect from Roche 122 117 240 198
Share of Alcon, Inc. reported net income 144 282
Catch-up for actual Alcon previous year net 2
income
Amortization of intangible assets -109 -217
Net income effect from Alcon 35 67
Net income from other associated companies 8 6 7 -4
Income from associated companies 130 158 247 261
On a comparable basis, excluding the impact of Alcon, the core results from
associated companies, which exclude the exceptional charges due to restructuring
and the amortization of intangible assets, increased by USD 16 million compared
to the prior-year period.
Financial income and interest expense
For the second quarter of 2011 financial income resulted in a net expense of USD
16 million (due to the inclusion of net currency losses recorded in this
category) compared to a financial income of USD 14 million in the year-ago
quarter. The decrease was attributable to the significant lower average
liquidity and a lower currency result. Interest expense remained stable with USD
190 million compared with USD 175 million in the prior year period.
Taxes
The tax rate (taxes as percentage of pre-tax income) decreased in the second
quarter of 2011 to 16.0% from 17.6% in the prior-year period, principally due to
the favorable impact of fully consolidating Alcon, Inc.
Net income
In the second quarter 2011, net income increased by 12% (17% cc) and core net
income increased 29% (31% cc).
Earnings per share
In the second quarter 2011 EPS increased by 7% (12% cc) and core EPS increased
by 23% (25% cc). The increase is lower than the growth of net income, which is
due to higher outstanding shares from the issuance of shares to purchase the
remaining Alcon non-controlling interest. The average number of shares
outstanding in second quarter 2011 rose 4.9% to 2 399.0 million from 2,287.7
million in the year-ago period, while a total of 2,426.5 million shares were
outstanding at June 30, 2011.
First half
Net sales
Net sales rose 21% (+16% cc) to USD 28.9 billion. Currency had a positive impact
of 5 percentage points as the dollar weakened against most currencies. Recently
launched products grew 47% over the first half of 2010, contributing USD 7.1
billion to total net sales for the Group.
Corporate income & expense, net
Corporate income & expense, which includes the costs of Group headquarters, was
below previous year, after taking into account an exceptional pension
curtailment gain of USD 265 million in the first half of 2010, as well as lower
corporate management and insurance costs.
Group operating income
Operating income advanced 4% (+7% cc), with unfavorable currency movements
depressing the result by 3 percentage points. Exceptional items in operating
income in the first half of 2011 include divestment gains in Pharmaceuticals on
the sale of ophthalmic pharmaceuticals required for approval of the Alcon merger
(USD 81 million), a gain of USD 183 million resulting from a legal settlement in
the Alcon Division and USD 324 million in divestment income from the sale of
Elidel®. These positive items were offset by charges and provisions for legal
cases (Sandoz USD 178 million), restructuring and impairment charges relating to
the streamlining of our manufacturing network (USD 99 million), the impairment
of financial assets in Vaccines & Diagnostics (USD 81 million), intangible asset
impairment charges in Pharmaceuticals (USD 107 million) and Alcon integration
costs net of a divestment gain of a lens care product (USD 71 million).
Income from associated companies
Income from associated companies decreased by 5% to USD 247 million. The income
from Roche increased from USD 198 million to 240 million due to higher estimated
income contribution offset by the shortfall of income from Alcon Inc. as it is
no longer accounted for as an associated company.
Financial income and interest expense
For the first half of 2011 financial income amounted to USD 6 million down from
USD 63 million mainly due to lower earnings from investments as a result of the
decreased average liquidity as well as a reduced currency result. Interest
expense increased by 23% from USD 308 million to USD 379 million due to the US
dollar bonds issued in March 2010.
Taxes
The tax rate (taxes as a percentage of pre-tax income) decreased to 16.0% in the
first half of 2011 from 17.0% in the 2010 period, principally due to the
favorable impact of fully consolidating Alcon, Inc.
Net income
Net income grew 3% (+7% cc) on strong operating income growth, benefiting from
an improved tax rate of 16.0% (from 17.0%), partially offset by lower income
from associated companies. Core net income increased 14% (+16% cc).
Earnings per share
Earnings per share (EPS) was USD 2.33, broadly in line with the previous year as
a result of the increased share count following the Alcon merger. Core EPS was
USD 2.88, an increase of 9% (+11% cc). The average number of shares outstanding
in the first half of 2011 rose 3.1% to 2 353.0 million from 2 282.8 million in
the year-ago period, while a total of 2 426.5 million shares were outstanding at
June 30, 2011.
Balance sheet
The total assets at June 30, 2011 amounted to USD 125.9 billion. These include
USD 65.1 billion of goodwill and intangible assets as a result of the
significant acquisitions made in recent years. Total non-current assets amounted
to USD 99.3 billion and increased only marginally during the period, mainly on
account of currency translation impacts. Current assets also stayed almost
constant at USD 26.6 billion over the six months however there were compensating
movements within the category as cash and marketable securities fell by USD 2.5
billion as a result of Alcon-related share purchases while inventories and trade
receivables both increased by USD 1.0 billion in line with business expansion.
Financial debt increased to USD 27.5 billion at June 30, 2011 from USD 23.0
billion at December 31, 2010 mainly as a result of the cash used for the
dividend payment, acquisition of additional Alcon non-controlling interests and
cash outflow for Novartis share repurchases. The long-term financial debt
comprises bonds and Euro Medium Term Notes totaling USD 13.1 billion and other
long-term financial loans of USD 0.8 billion. The short-term financial debt
comprises commercial paper of USD 6.0 billion and other short-term borrowings
totaling USD 7.6 billion. Non-financial debt liabilities increased by USD 0.8
billion to USD 31.3 billion compared to USD 30.5 billion at December 31, 2010.
The Group´s equity fell by USD 2.7 billion to USD 67.1 billion at June 30, 2011
compared to December 31, 2010. This was the result of an increase due to
comprehensive income for the period of USD 7.6 billion, principally due to the
2011 first half net income of USD 5.5 billion and positive currency translation
movements of USD 2.3 billion, and equity-based compensation of USD 0.4 billion,
which was more than offset by the total of dividends for the period of USD 5.4
billion and USD 2.3 billion net for the purchase of treasury shares coupled with
the net effect of acquiring the remaining non-controlling interest in Alcon,
Inc., which totalled USD 2.9 billion. The acquisition of the remaining interest
in Alcon, Inc. was achieved by acquiring 4.8% of the non-controlling interest
for USD 2.4 billion prior to the merger and acquiring the remaining non-
controlling interest through the merger on April 8, 2011 by issuance of Novartis
shares with a fair value of USD 9.2 billion and a contingent value payment of
USD 0.5 billion, resulting in the elimination of non-controlling interest of USD
6.5 billion and a reduction in equity due to the excess of the amount exchanged
over the recorded value of the non-controlling interest of USD 5.6 billion.
The Group´s debt/equity ratio rose to 0.41:1 at June 30, 2011, compared to
0.33:1 at the end of 2010, reflecting the higher financial debt for the funding
of the Alcon acquisition. The Group´s liquidity decreased from USD 8.1 billion
at the end of 2010 to USD 5.6 billion at June 30, 2011. Net debt at June
30, 2011 was USD 21.9 billion compared to USD 14.9 billion at the end of the
previous year.
Cash flow
Cash flow from operating activities of USD 5.4 billion in the first half of
2011 was impacted by higher financing expenses as well as higher working capital
requirements compared to the prior year. The interest and other financial
receipts resulted in a net outflow of USD 0.2 billion compared to a net inflow
of USD 0.7 billion in the year ago period. The funds tied up in working capital
increased by USD 0.7 billion compared to the prior year first half due to the
acquisition of Alcon and to business requirements to support growth initiatives
but also due to the low prior year base which benefited from collections from
A(H1N1) sales. As a result, the cash flow from operating activities was lower by
USD 0.9 billion compared to the prior year amount of USD 6.3 billion.
The cash flow from investing activities provided USD 0.6 billion as the proceeds
from sale of marketable securities (USD 1.6 billion) and from the sale of
tangible and intangible assets (USD 0.7 billion, mainly from Elidel® marketing
rights) exceeded the investments of USD 1.1 billion in tangible, intangible and
financial assets and outflow of USD 0.6 billion for acquisitions, mainly for
Genoptix, Inc. In the year-ago period, the investing activities produced a cash
outflow of USD 4.5 billion due investments in marketable securities.
Cash outflow from financing activities amounted to USD 7.0 billion in the first
half of 2011. This amount is comprised of the dividend payment for 2010 of USD
5.4 billion, a net amount of USD 2.1 billion for the acquisition of treasury
shares and USD 3.2 billion for the acquisition of Alcon. These outflows were
partially financed by an increase in short term borrowings of USD 3.7 billion.
The cash flow from financing activities in the year-ago period was an inflow of
USD 1.0 billion as inflow from bond issues and treasury share transactions of
USD 5.5 billion were partly offset by the dividend payment of USD 4.5 billion.
The free cash flow represents an outflow of USD 0.4 billion as the cash flow
from operating activities of USD 5.4 billion and net investments in tangible and
intangible assets of USD 0.4 billion were lower than the payment of the 2010
dividend of USD 5.4 billion paid in February 2011.
INNOVATION REVIEW
Key developments in the second quarter of 2011:
* Afinitor( )(everolimus) was approved in the US for the treatment of
progressive neuroendocrine tumors (NET) of pancreatic origin in patients
with unresectable, locally advanced or metastatic disease. In addition,
everolimus received approval in Switzerland under the trade name Votubia for
the treatment of patients three years of age and older with subependymal
giant cell astryocytoma (SEGA) associated with tuberous sclerosis for whom
surgery is not a suitable option. The Committee for Medicinal Products for
Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive
opinion for Votubia as a treatment in this patient population in the EU.
* The European Commission approved Lucentis (ranibizumab) for visual
impairment due to macular edema secondary to both branch and central forms
of retinal vein occlusion (RVO). Approval of Lucentis was based on data from
two pivotal Phase III studies that showed early and sustained vision
improvement in patients at six months of monthly Lucentis treatment compared
to standard of care, with visual acuity gains maintained from months 7
through 12 with as-needed dosing of Lucentis.
* The European Commission approved Rasilamlo, a single-pill combination of
aliskiren and amlodipine, for the treatment of patients suffering from
hypertension not controlled by either aliskiren or amlodipine alone.
* In July, the US Food and Drug Administration (FDA) approved once-daily
Arcapta Neohaler (indacaterol inhalation powder) 75 mcg for the long-term
maintenance bronchodilator treatment of airflow obstruction in patients with
chronic obstructive pulmonary disease (COPD), including chronic bronchitis
and/or emphysema. This decision makes Arcapta Neohaler the first once-daily
therapy in the long-acting beta-2 agonist class to be approved in the US for
COPD patients. Also in July, Indacaterol (in a 150 mcg once-daily dose)
received regulatory approval in Japan under the trade name Onbrez Inhalation
Capsules for the treatment of COPD.
* The Japanese Ministry of Health, Labour and Welfare approved Exelon
(rivastigmine) Patch for patients with mild-to-moderate dementia due to
Alzheimer´s disease. The drug is approved in the US and EU for the same
indication.
* A marketing authorization application was submitted to the EMA for Janus
kinase inhibitor INC424 (ruxolitinib) for the treatment of myelofibrosis, a
blood cancer characterized by bone marrow failure and an enlarged spleen.
The filing is based on results from two Phase III studies, COMFORT-I and
COMFORT-II. COMFORT-I compared INC424 to placebo at 24 weeks and showed that
41.9% of treated patients achieved at least a 35% reduction in spleen volume
compared to 0.7% of placebo patients (p<0.0001). COMFORT-II compared INC424
to the best available therapy at 48 weeks and demonstrated that INC424
produced a reduction in spleen volume of 35% or greater in 28.5% of patients
compared to 0% of patients treated with the best available therapy
(p<0.0001).
* Results from the Phase III GLOW2 study in patients with chronic obstructive
pulmonary disease (COPD) showed that NVA237 provided a significant level of
bronchodilation, measured by 24-hour trough FEV1, compared to placebo. The
study included an exploratory comparison against open-label tiotropium, and
the effect observed with NVA237 was similar to that seen with tiotropium.
Overall, NVA237 was well tolerated by patients, with the number of adverse
events similar to or lower than placebo. These results will form the basis
of regulatory filings planned for later this year.
* A Phase III study showed a significant survival benefit for patients with
resected KIT+ gastrointestinal stromal tumors who received adjuvant Glivec
(imatinib) treatment for three years following surgery as compared to one
year following surgery. The results, gathered five years after surgery,
showed that 66% of patients taking adjuvant Glivec therapy for three years
remained free of cancer recurrence (primary endpoint) compared to 48% of
those who had received adjuvant Glivec therapy for only one year (p<.0001).
Moreover, 92% of patients taking Glivec for three years had survived to the
five-year mark (secondary endpoint), compared to 82% of those who had
received Glivec for only one year (p=.019). These clinical data will be
submitted to regulatory authorities in the second half of 2011 to support
extended adjuvant Glivec treatment of three years.
* A Phase III study of Afinitor in patients with tuberous sclerosis complex,
the largest prospective clinical trial in Phase III to date in this patient
population, met the primary endpoint of reduction in subependymal giant cell
astrocytoma (SEGA) volume. Results showed that more than one-third of
patients taking Afinitor experienced a 50% or greater reduction in the size
of their SEGAs versus 0% on placebo.
* In July, an interim analysis of a pivotal Phase III study showed that
Afinitor in combination with exemestane significantly extended progression-
free survival (PFS) when compared to placebo plus exemestane in
postmenopausal women with ER+HER2- metastatic breast cancer whose disease
has progressed, despite initial endocrine therapy. The trial was stopped
early after interim results showed the primary endpoint of PFS was met.
Results will be presented at an upcoming medical conference and worldwide
regulatory filings expected in the second half of 2011.
* Results from two pivotal Phase III studies, presented at the 2011 European
League Against Rheumatism (EULAR) Congress, showed that ACZ885 (canakinumab)
provided better pain relief during acute attacks and reduced the risk of new
attacks compared with injectable steroid (triamcinolone acetonide) in gouty
arthritis patients contraindicated, intolerant or unresponsive to non-
steroidal anti-inflammatory drugs and/or colchicine. Regulatory filings for
the use of ACZ885 in this patient population have been submitted in the EU,
US, Canada and Switzerland. An FDA Advisory Committee endorsed the overall
efficacy but not the overall safety of ACZ885 in this patient population,
voting against approval in the proposed indication. The committee members
raised the potential for use in a narrower population of gouty arthritis
patients, and Novartis is currently working with the FDA to identify the
right patients who might benefit from this therapy.
* Novartis amended its application to the EMA for Afinitor as a treatment of
advanced NET of gastrointestinal, lung or pancreatic origin to include only
advanced pancreatic NET. Afinitor received approval in the US for this
indication earlier this year. The current median survival duration for
patients with advanced pancreatic NET is only 24 months, and Afinitor holds
promise for addressing this critical area of patient need.
* The FDA accepted the application to expand the Menveo indication to include
infants and toddlers as young as two months, based on data from more than
6,000 children between the ages of 2 and 23 months worldwide. If approved,
Menveo would be the first quadrivalent meningococcal conjugate vaccine to
provide protection in the first year of life, when the majority of these
infections occur.
* Three studies of Bexsero, presented at The European Society for Paediatric
Infectious Diseases (ESPID), showed significant potential in providing broad
coverage against meningococcal serogroup B (MenB) infections. The first
study, in more than 1,800 infants, showed that Bexsero induces a robust
immune response to MenB when given alone or when co-administered with other
routine vaccines. Data from the second study, in more than 1,500 toddlers,
showed that Bexsero provides protective immune response when used as a
booster in toddlers already primed, or after two doses in those not
previously vaccinated with Bexsero. A third study presented showed that
Bexsero induces a strong immune response in adolescents against MenB.
A full pipeline update can be found on our website at http://www.novartis.com.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "commitment, " "strategy, " "expect, " "momentum, "
"promise, " "potential, " "might, " "will, " "plan, " "planning, " "sustainability, "
"future, " "committed, " "outlook, " "expected, " "aim, " "expecting, " "pending, "
"planned, " "would, " or similar expressions, or by express or implied discussions
regarding potential new products, potential new indications for existing
products, or regarding potential future revenues from any such products; or
regarding potential growth opportunities from the merger of Alcon and Novartis,
or the potential impact on Alcon or Novartis of the merger;, or any potential
synergies, strategic benefits or opportunities as a result of the merger; or
regarding potential future sales or earnings of the Novartis Group or any of its
divisions as a result of the merger or otherwise; or by discussions of strategy,
plans, expectations or intentions. You should not place undue reliance on these
statements. Such forward-looking statements reflect the current views of the
Group regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or
implied by such statements. There can be no guarantee that any new products will
be approved for sale in any market, or that any new indications will be approved
for existing products in any market, or that such products will achieve any
particular revenue levels. Nor can there be any guarantee that Novartis will be
able to realize any of the potential synergies, strategic benefits or
opportunities as a result of the merger with Alcon. Nor can there be any
guarantee that the Novartis Group, or any of its divisions, will achieve any
particular financial results, whether as a result of the merger or otherwise. In
particular, management´s expectations could be affected by, among other things,
unexpected regulatory actions or delays or government regulation generally;
unexpected clinical trial results, including additional analyses of existing
clinical data or unexpected new clinical data; the Group´s ability to obtain or
maintain patent or other proprietary intellectual property protection;
disruptions from the merger and integration with Alcon making it more difficult
to maintain business and operational relationships, and relationships with key
employees; unexpected product manufacturing issues; uncertainties regarding
actual or potential legal proceedings, including, among others, product
liability litigation, litigation regarding sales and marketing practices,
government investigations and intellectual property disputes; competition in
general; government, industry, and general public pricing and other political
pressures; uncertainties regarding the after-effects of the recent global
financial and economic crisis; uncertainties regarding future global exchange
rates and uncertainties regarding future demand for our products; uncertainties
involved in the development of new healthcare products; the impact that the
foregoing factors could have on the values attributed to the Group´s assets and
liabilities as recorded in the Group´s consolidated balance sheet; and other
risks and factors referred to in Novartis AG´s current Form 20-F on file with
the US Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those described herein as anticipated,
believed, estimated or expected. Novartis is providing the information in this
release as of this date and does not undertake any obligation to update any
forward-looking statements as a result of new information, future events or
otherwise.
About Novartis
Novartis provides healthcare solutions that address the evolving needs of
patients and societies. Focused solely on healthcare, Novartis offers a
diversified portfolio to best meet these needs: innovative medicines, eye care,
cost-saving generic pharmaceuticals, consumer health products, preventive
vaccines and diagnostic tools. Novartis is the only company with leading
positions in these areas. In 2010, the Group´s continuing operations achieved
net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1
billion excluding impairment and amortization charges) was invested in R&D
throughout the Group. Headquartered in Basel, Switzerland, Novartis Group
companies employ approximately 121,000 full-time-equivalent associates and
operate in more than 140 countries around the world. For more information,
please visit http://www.novartis.com.
Important dates
September 13, 2011 Novartis Innovation and Strategy Forum II/Alcon Day
October 25, 2011 Third quarter results 2011
January 25, 2012 Fourth quarter and full year results 2011
All product names appearing in italics are trademarks owned by or licensed to
Novartis Group Companies.
Please find full media release in English attached and on the following link:
http://hugin.info/134323/R/1531807/466295.pdf
Further language versions are available through the following links:
German version is available through the following link:
http://hugin.info/134323/R/1531807/466296.pdf
French version is available through the following link:
http://hugin.info/134323/R/1531807/466297.pdf
--- End of Message ---
Novartis International AG
Postfach Basel
WKN: 904278;ISIN: CH0012005267;
Media release (PDF):
http://hugin.info/134323/R/1531807/466295.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1531819]
CH0012005267
